RESUMO
The interaction potential of Cynara scolymus L., Mikania glomerata Spreng.,Rhamnus purshiana DC and Uncaria tomentosa (Willd. Ex Roem. & Schult.) with conventional drugs metabolized by the CYP3A4 metabolic route was tested in HeLa cell lines, using the in vitro model of the hPXR. The herbal medicines C. scolymus (1.5 mg/mL dry extract) did not affect the receptor. On the other hand, M. glomerata (5.5 mg/mL dry extract), R. purshiana (1.5 mg/mL dry extract), and U. tomentosa (2.0 mg/mL dry extract) showed to be hPXR agonist, suggesting a potential interaction with the conventional drugs metabolized by the same isoforms of the CYP superfamily. The results from this study contribute to the use safer and more effective of these herbal medicines.
Se evaluó el potencial de interacción de Cynara scolymus L., Mikania glomerata Spreng., Rhamnus purshiana DC y Uncaria tomentosa (Willd. Ex Roem. & Schult.) con fármacos convencionales metabolizados por la ruta metabólica CYP3A4 en líneas celulares HeLa, utilizando el modelo in vitro del hPXR. Las hierbas medicinales C. scolymus (1,5 mg/mL de extracto seco) no afectaron al receptor. Por otro lado, M. glomerata (5.5 mg/mL de extracto seco), R. purshiana (1.5 mg/mL de extracto seco) y U. tomentosa (2.0 mg/mL de extracto seco) mostraron ser agonistas de hPXR, lo que sugiere una potencial interacción con los fármacos convencionales metabolizados por las mismas isoformas de la superfamilia CYP. Los resultados de este estudio contribuyen a un uso más seguro y eficaz de estos medicamentos a base de hierbas medicinales.
Assuntos
Rhamnus , Unha-de-Gato , Cynara scolymus , Mikania , Interações Ervas-Drogas , Plantas Medicinais , Técnicas In Vitro , Indutores do Citocromo P-450 CYP3A/químicaRESUMO
Prostate cancer remains a health problem for men. Targeting androgen (AR) and estrogen (ER) receptors improves the outcomes of the disease, and many medicinal plants exert their effects by modulating these pathways. Therefore, a systematic review was conducted to identify medicinal plants and their natural compounds that may modulate the AR and/or ER pathways in cell and animal models. A search was conducted across EMBASE, LILACS, PubMed, Scopus, and Web of Science, with grey literature from Google SCHOLAR and ProQuest. Two authors independently selected eligible studies based on their titles and abstracts, and a third author resolved conflicts. Then, data from the full text of eligible studies were extracted and synthesized. In total, 75 studies were included. Results showed the effects of several different medicinal plants and natural compounds in reduction of AR and/or ER transcription and translation and AR secondary effects: cell growth reduction, induction of apoptosis, and cell cycle arrest. In animal models, tumor size reduction, increase in apoptosis, and downregulation of AR expression in tumors were also observed. No single phytochemical group concentrating molecules with anti-AR and/or ER activity was identified. Nevertheless, several phytochemical compounds showed potential for future clinical studies in the management of the disease.